Supernatant from a coculture of macrophages and irradiated leukocytes, for controlling tumour progression or restoring anti-tumor immunity
US12115188B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2019 |
| Grant date | Oct 15, 2024 |
| Priority date | — |
| Expiry date | Aug 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method for the resolution of pro-tumour inflammation by means of a pharmaceutical preparation. Leukocytes are isolated from the buffy coat obtained from whole blood and a portion of the leukocytes is placed in a first pouch receiving a differentiation factor and stored in conditions that preserve cellular viability for several days, before a defined, fresh culture medium is supplied, after which said leukocyte portion is left to rest for a further several days, which results in the production of macrophages. A further portion of the leukocytes is placed in a second pouch and irradiated therein. The two pouches are then mixed and the supernatant is recovered to serve as pharmaceutical preparation. The invention also relates to the use in the treatment of cancers, either alone or in combination with other therapies, in human and veterinary medicine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.